[Immunohistochemical detection of growth hormone-releasing factor (GRF) in neuroendocrine tumors].
We examined formalin-fixed, paraffin-embedded human tumors (42) from autopsies and surgical specimens for the presence of human pancreatic GRF-40 using the unlabeled antibody peroxidase-antiperoxidase method to assess the prevalence of tumors containing GRF, to define their primary sites and cellular derivations, and to correlate clinical and pathological features. Two paragangliomas, 1 pancreatic endocrine tumor, 1 bronchial carcinoid and 1 ganglioneuroma were immunoreactive for GRF. Of the GRF-containing tumors, only one bronchial carcinoid and one paraganglioma were associated with acromegaly.
Gottschalk
J
J
Institut für Pathologie, Humboldt-Universität zu Berlin.
Rohde
W
W
D003528:Carcinoma, Adenoid Cystic / Q000032:analysis; D005729:Ganglioneuroma / Q000032:analysis; D013007:Growth Hormone-Releasing Hormone / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D007150:Immunohistochemistry; D009369:Neoplasms / Q000032:analysis*; D009490:Neurosecretory Systems / Q000032:analysis*; D010190:Pancreatic Neoplasms / Q000032:analysis; D010235:Paraganglioma / Q000032:analysis
D013007:Growth Hormone-Releasing Hormone
Immunhistochemischer Nachweis des Growth hormone-releasing factor (GRF) in neuroendokrinen Tumoren.